BillionToOne: Funding, Investors & Team (Oct 2026)
BillionToOne is a precision diagnostics company that uses technology to accurately count DNA molecules at a single-count level, making molecular diagnostics more accurate, efficient, and accessible. The company's goal is to make prenatal testing safe and affordable for all expecting mothers, detecting genetic disorders like thalassemia through a simple blood test. Instead of invasive procedures like amniocentesis, which carries a high risk of miscarriage, BillionToOne offers a safe and affordable alternative in developing countries. Established in 2016, the company is based in Menlo Park, California.
BillionToOne has raised $249M across 4 funding rounds on record, the most recent a Series D of $130M announced in Jun 2024.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
BillionToOne Company Profile and Key Stats
Latest funding round on record: Jun 2024.
BillionToOne Funding Rounds
BillionToOne raised $15.0M in an undisclosed round announced in Mar 2020.
1.3 years later, an undisclosed round of $55.0M was announced in Jun 2021.
1.5 years later, a Series C of $48.5M was announced in Dec 2022.
1.5 years later, a Series D of $130M was announced in Jun 2024.
BillionToOne Founders and Leadership Team
Contact details for the BillionToOne team: 1 of 1 has an email address on file.
Start 14-day free trial →BillionToOne Funding Compared to Other Biotechnology Startups
BillionToOne's latest round of $130M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like BillionToOne in Biotechnology and Menlo Park
Companies Similar to BillionToOne
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
BillionToOne Funding FAQs
What does BillionToOne do?
BillionToOne is a precision diagnostics company that uses technology to accurately count DNA molecules at a single-count level, making molecular diagnostics more accurate, efficient, and accessible. The company's goal is to make prenatal testing safe and affordable for all expecting mothers, detecting genetic disorders like thalassemia through a simple blood test. Instead of invasive procedures like amniocentesis, which carries a high risk of miscarriage, BillionToOne offers a safe and affordable alternative in developing countries. Established in 2016, the company is based in Menlo Park, California.
How much funding has BillionToOne raised?
BillionToOne has raised $249M across 4 rounds on record. The most recent is a Series D of $130M announced in Jun 2024.
When did BillionToOne last raise funding?
BillionToOne's most recent funding round on record is a Series D of $130M, announced in Jun 2024.
Who founded BillionToOne?
FundedIQ lists Oguzhan Atay (Founder) at BillionToOne.
Where is BillionToOne headquartered?
BillionToOne is based in Menlo Park, California, United States.
How many employees does BillionToOne have?
BillionToOne is in the 251-500 employee band.
How does BillionToOne's funding compare to other Biotechnology startups?
BillionToOne's latest round of $130M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's BillionToOne Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for BillionToOne is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.